Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2025; 17(11): 113262
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.113262
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.113262
FGFR2 fusions as novel oncogenic drivers in gastrointestinal stromal tumors: Two case reports and review of literature
Yan-Yun Hong, Chun-Hui Shou, Wei-Li Yang, Xiao-Dong Wang, Qing Zhang, Xiao-Sun Liu, Ji-Ren Yu, Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China
Author contributions: Hong YY, Shou CH, Zhang Q, and Yu JR conceived and designed the study; Wang XD, Zhang Q, and Yang WL performed the procedures; Hong YY, Shou CH, and Zhang Q collected the data; Hong YY, Shou CH, Liu XS, and Yu JR analyzed and interpreted the data; Hong YY, Shou CH, Liu XS, and Yu JR wrote the manuscript; all authors have read and approved the final manuscript.
Informed consent statement: Owing to this study’s retrospective nature and minimal risks, the requirement for written informed consent was waived. The authors thank the patients’ family members for their cooperation and regular follow-ups.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ji-Ren Yu, PhD, Professor, Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310000, Zhejiang Province, China. yujr0909@zju.edu.cn
Received: August 21, 2025
Revised: September 21, 2025
Accepted: October 9, 2025
Published online: November 15, 2025
Processing time: 85 Days and 8.7 Hours
Revised: September 21, 2025
Accepted: October 9, 2025
Published online: November 15, 2025
Processing time: 85 Days and 8.7 Hours
Core Tip
Core Tip: Herein, we report, for the first time, novel FGFR2 rearrangements FGFR2-CIT/intergenic-FGFR2 and FGFR2-CAMK2G/FGFR2-VCL fusions as potential primary oncogenic drivers in two patients with KIT/PDGFRA wild-type gastrointestinal stromal tumors (GISTs). Both patients achieved sustained remission following adjuvant imatinib, challenging the notion that non-canonical alterations preclude tyrosine kinase inhibitor response. These findings might expand the molecular spectrum of GISTs and suggest that FGFR2 fusions might define a distinct subtype with potential sensitivity to FGFR-targeted therapies, offering new avenues for precision treatment in imatinib-resistant or advanced disease cases.